RT Journal Article
SR Electronic
T1 Marked heterogeneity in malaria infection risk in a Malian longitudinal cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.20.24312307
DO 10.1101/2024.08.20.24312307
A1 LaVerriere, Emily
A1 Johnson, Zachary M.
A1 Shieh, Meg
A1 Nziza, Nadege
A1 Alter, Galit
A1 Buckee, Caroline O.
A1 Crompton, Peter D.
A1 Traore, Boubacar
A1 Tran, Tuan M.
A1 Neafsey, Daniel E.
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.20.24312307.abstract
AB Variation in malaria infection risk, a product of disease exposure and immunity, is poorly understood. We genotypically profiled over 13,000 blood samples from a six-year longitudinal cohort in Mali to characterize malaria infection dynamics with unprecedented detail. We generated Plasmodium falciparum amplicon sequencing data from 464 participants (aged 3 months -25 years) across the six-month 2011 transmission season and profiled a subset of 120 participants across the subsequent five annual transmission seasons. We measured infection risk as the molecular force of infection (molFOI, number of genetically distinct parasites acquired over time). We found that molFOI varied extensively among individuals (0-55 in 2011) but was independent of age and consistent within individuals over multiple seasons. Reported bednet usage was nearly universal. The HbS allele associated with lower molFOI, and functional antibody signatures correlated with both low and high molFOI participants, identifying candidate immune correlates of protection and risk, respectively. The large inter-individual variability in molFOI and consistency of intra-individual infection risk over time remains largely unexplained, but should be considered in clinical trials and implementation of malaria interventions. Factors contributing to heterogeneity in infection risk should be further studied to inform development of future malaria interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by an NIH R01 award to DEN (R01AI141544). The original Mali cohort study was funded by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Kalifabougou cohort study was approved by the Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique and Technology of Bamako, and the Institutional Review Board of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH IRB protocol number: 11IN126; https://clinicaltrials.gov/; trial number NCT01322581).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll sequencing data will be available through the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) under accession PRJNA1129562. The code used to process sequencing data is available at https://github.com/broadinstitute/malaria-amplicon-pipeline.